Kidney Week

Abstract: FR-PO239

Effects of Brazilian Green Propolis Extract on Proteinuria in CKD Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Session Information

• CKD: Clinical, Outcomes, Trials - II
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Silveira, Marcelo Duarte, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

Marcelo Duarte Silveira,

• Teles de Farias Filho, Flavio, Federal University of Alagoas, Maceio, AL, Brazil

Flavio Teles de Farias Filho,

• Berretta, Andresa, Apis Flora Indl. Coml. Ltda., Ribeirao Preto, SP, Brazil

Andresa Berretta,

• Rodrigues, Camila Eleuterio, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

Camila Eleuterio Rodrigues,

• Sanches, Talita R., University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

Talita R. Sanches,

• Seguro, Antonio C., University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

Antonio C. Seguro,

• Andrade, Lucia, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

Lucia Andrade,

Background

Chronic kidney disease (CKD) is a public health problem of global proportions, and proteinuria is associated with disease progression. Brazilian green propolis (GP) is a natural resin that bees collect from plant sap, presenting anti-inflammatory, immunomodulatory and anti-oxidant properties. We tried to determine whether GP extract can reduce proteinuria and alter the estimated glomerular filtration rate (eGFR).

Methods

This was a randomized, double-blind, placebo-controlled study including 32 patients with diabetic or non-diabetic CKD; between 18 and 90 years of age; with an eGFR of 25-70 ml/min/1.73m²; and with proteinuria (>300mg/day) or micro- or macro-albuminuria (urine albumin-to-creatinine ratio >30mg/g uCr or >300mg/g uCr, respectively). The patients were randomly assigned to receive GP (n=18) or placebo (n=14) at a dose of 500 mg/day and were followed for 12 months.

Results

Proteinuria (mg/24h) was significantly lower in the GP group than in the placebo group—695 (95% CI: 483-999) vs. 1403 (95% CI: 1031-1909)—(p=0.004). This finding was independent of variations in eGFR and systemic hemodynamics, which did not show differences between the groups during the follow-up. There was also a significant reduction of the urinary monocyte chemoattractant protein-1 (pg/mg uCr) was also significantly lower in the GP group than in the placebo group—58 (95% CI: 36-95) vs. 98 (95% CI: 62-155)—(p=0.038). At the dose used, GP was found to be safe and well tolerated.

Conclusion

Our findings broaden the perspectives for the use of GP as a natural adjuvant in reducing proteinuria in CKD. (ClinicalTrials.gov identifier: NCT02766036; Supported by FAPESP)

* P = 0.023; † P = 0.006; ‡ P = 0.004; Propolis vs. Placebo.

Funding

• Government Support - Non-U.S.